Opinion|Videos|October 2, 2024 (Updated: October 2, 2024)
Navigating Non-Response: A Holistic Approach to Patient Care
Gus Alva, MD, DFAPA; Carmen Kosicek, MSN, PMHNP-BC; and Roger McIntyre, MD, FRCPC, focus on social determinants of health and MDD commenting on treatment augmentation, and integrative approaches like social prescribing.
Advertisement
Episodes in this series
Advertisement
Related to this article
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.
Advertisement
Advertisement
Trending on Psychiatric Times
1
MDD Side Effect Profiles: Counseling, Adherence, and Suicidality Monitoring
2
Synapse-Level Mapping Could Reveal How Disrupted Brain Circuits Lead to Psychiatric Disorders
3
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
4
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
5